Virtual Library

Start Your Search

Xiaohui Chen



Author of

  • +

    P1.03 - Biology (Not CME Accredited Session) (ID 935)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.03-23 - The Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study (ID 11224)

      16:45 - 18:00  |  Presenting Author(s): Xiaohui Chen

      • Abstract
      • Slides

      Background

      The identification and clinical validation of cancer driver genes are essential to accelerate the translational transition of cancer genomics, as well as to find clinically confident targets for the therapeutic intervention of cancers. While the genetic variability of neurotrophic receptor tyrosine kinase 1 (NTRK1) mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring NTRK1 mutations.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A total of 389 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of NTRK1 mutation and other genes were detected by next generation sequencing.

      4c3880bb027f159e801041b1021e88e8 Result

      NTRK1 gene mutation rate was 4.11% (16/389) in non-small cell lung cancer, including H268Q (1 patient), V181M (1 patient), Q459R (1 patient), G726C (1 patient), R89H (1 patient), M635I (1 patient), L126Q (1 patient), G138R (1 patient), E245A (1 patient), M530T (1 patient), L549Cfs*73 (1 patient), N293S (1 patient), E245A (1 patient), W236C (1 patient), E456K (1 patient) and F297L (1 patient), and median overall survival (OS) for these patients was 11.0 months. Among them, all patients were NTRK1 gene with co-occurring mutation. Briefly, patients with (n=5) or without (n=11) co-occurring EGFR mutations had a median OS of 14.0 months and 11.0 months respectively (P=0.90); patients with (n=12) or without (n=4) co-occurring TP53 mutations had a median OS of 11.0 months and 6.0 months respectively (P=0.67); patients with (n=3) or without (n=13) co-occurring BRAF mutations had a median OS of 14.0 months and 11.0 months respectively (P=0.43); patients with (n=4) or without (n=16) co-occurring CDKN2A mutations had a median OS of 3.5 months and 14.0 months respectively (P<0.01).

      8eea62084ca7e541d918e823422bd82e Conclusion

      NTRK1 oncogenic activation through gene fusion defines a novel and distinct subset of NSCLC. EGFR, TP53 and BRAF gene accompanied may have less correlation with KIT mutation in NSCLC patients. CDKN2A accompanied mutations might play a worse prognosis in NTRK1 gene mutation non-small cell lung cancer.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.03 - Biology (Not CME Accredited Session) (ID 952)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.03-09 - The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study (ID 11307)

      16:45 - 18:00  |  Author(s): Xiaohui Chen

      • Abstract
      • Slides

      Background

      NTRK fusions have been recently identified as a therapeutic target in a rare fraction of Caucasian patients with lung cancer (3.3%). The aim of this study was to evaluate the prevalence of NTRK fusions in Chinese lung cancer populations, which had not been reported earlier, and to describe targeting potential in Chinese lung cancer populations.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A multicenter study in China was initiated from February 2014, and lung cancer patients have been enrolled as of December 2017. Capture-based comprehensive genomic profiling was performed on 2719 lung cancer FFPE samples (non-squamous/squamous/small=2061/349/309) sequenced to a mean coverage depth of > 650X for up to 381 cancer-related genes. Genomic alterations (GA) included short variant (SV) base subs and insertions/deletions, copy number alterations, and rearrangements/fusions. Tumor mutational burden (TMB; mut/Mb) was calculated on up to 1.2 Mb of sequenced DNA.

      4c3880bb027f159e801041b1021e88e8 Result

      Of this entire cohort, just one (0.04%) patient was identified with a TPM3-NTRK1 fusion. The patient was diagnosed with SCLC. TPM3-NTRK1 fusion was found by biopsy using NGS, the genes co-altered with NTRK fusion was no concurrent with KRAS, EGFR, ALK, ROS1, or other known drivers were identified in the study cohort cases.

      8eea62084ca7e541d918e823422bd82e Conclusion

      NTRK fusions are a rare molecular subtype in Chinese lung cancer populations. Given clinical evidence for the activity of targeted therapy approaches, molecular eligibility for clinical trials of larotrectinib or entrectinib should include these fusion subtypes. The clinical evidence for responsiveness of NTRK fusions driven lung cancer provides an opportunity to personalize treatments and improve clinical outcomes for patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.